Tesamorelin during treatment and afterwards
The fat reduction deserves credit. So does the follow-up that recorded its return after treatment ended.
Follow-up through 52 weeks
The 52-week programme in adults with HIV and abdominal fat accumulation included 273 participants receiving tesamorelin and 137 receiving placebo. Visceral fat reduction was sustained at approximately 18% over the year, P<0.001 versus baseline. Visceral fat reaccumulated after discontinuation.
I resent seeing that return relegated to a footnote. It describes the duration of the result. A treatment can have value while it continues; the follow-up makes clear that the measured change was contingent on continued administration. That is a more useful account than a photograph suggesting a permanent transformation.
Fat measurements
Visceral fat sits deep in the abdomen, around internal organs. The 2014 randomized trial in 50 antiretroviral-treated adults with HIV measured visceral and liver fat over 6 months. The treatment effect on visceral fat was -42 cm2, P=0.005; the net change in hepatic lipid-to-water percentage was -2.9%, P=0.003.
The 2026 meta-analysis of five randomized trials in HIV-associated lipodystrophy found a mean visceral adipose tissue reduction of 27.71 cm2 versus placebo, with a 95% confidence interval of -38.37 to -17.06. It also reported lower trunk fat and hepatic fat fraction and increased lean body mass.
These are substantial human findings for this group of peptides. These human measurements deserve more credit from me than a general expectation of looking leaner, while retaining the population that produced them: adults with HIV-associated lipodystrophy. General fat-loss claims in people without HIV require their own evidence.
The GHRH connection
Tesamorelin is a synthetic 44-amino-acid GHRH analog with an N-terminal modification that resists enzymatic breakdown. It stimulates pituitary GH release and downstream IGF-1. The GHRH-analogue review explains its relationship to the shorter sermorelin fragment and the albumin-binding CJC-1295 DAC design.
In a study of 13 healthy men over 2 weeks, overnight GH and IGF-1 rose, while fasting glucose and insulin-stimulated glucose uptake were not significantly affected. That short mechanistic observation in healthy men earns a cautious nod from me. The visceral-fat trials answer a different clinical question in a different population.
Glucose, swelling and cancer concerns
The 52-week programme reported no clinically significant changes in glucose parameters. That observation deserves its place alongside the broader concern that GH stimulation can affect insulin sensitivity. Trials also reported local injection reactions, peripheral edema and arthralgias, or joint pain. Active malignancy is a labeled contraindication, and long-term oncologic safety remains incompletely characterized.
The LiverTox monograph classifies tesamorelin as an unlikely cause of clinically apparent liver injury, with no attributable cases reported there. I welcome a reassuring result when it is specific about the harm assessed. Liver safety, glucose effects and long-term tumor risk remain separate questions.
HIV-specific approval
Tesamorelin received U.S. approval in 2010 for excess abdominal fat in adults with HIV-associated lipodystrophy. General fat loss, anti-aging, muscle-building and cognitive enhancement lie outside that approval; those uses are off-label and investigational. Research-grade material also lacks the quality assurance of the approved pharmaceutical product. Tesamorelin is prohibited in sport under WADA S2, in and out of competition.
Of these four compounds, tesamorelin has the strongest human outcome record for its specific indication. My favorable judgment ends at those boundaries. The sermorelin page follows a different success, measured as height growth in children with GH deficiency.